SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT

SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT

Objective: Androgen pathway inhibitors have a significant impact on the treatment of prostate cancer. The treatment approach is controversial in patients who develop oligo-progression under anti-androgen therapy. This study aimed to investigate the effects of metastasis-directed stereotactic body ra...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sabin Göktaş Aydın, Yasin Kutlu, Harun Muğlu, Özgür Açıkgöz, Ahmet Aydın, Ahmet Bilici, Ömer Fatih Ölmez, Dilek Ünal, Ebru Karcı, Özcan Yıldız
Format:	Article
Language:	English
Published:	Istanbul University Press 2023-03-01
Series:	İstanbul Tıp Fakültesi Dergisi
Subjects:	stereotactic body radiotherapy abiraterone enzalutamide castration-resistant prostate cancer
Online Access:	https://cdn.istanbul.edu.tr/file/JTA6CLJ8T5/5B2A0BD8E45B4E26BD23A47060EF6D1D
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01)

Short-term efficacy of enzalutamide in treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer
by: MEI Jingchang, SU Xiaonan, YAO Yu, GUAN Fengju, ZHANG Guiming
Published: (2025-02-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

A Super‐Enhancer‐Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration‐Resistant Prostate Cancer
by: Liling Jiang, et al.
Published: (2025-08-01)

Safety and Efficacy of Reduced Dose of Enzalutamide in Patients with Castration-Resistant Prostate Cancer: A Systematic Review
by: Zineddine Belabaci, et al.
Published: (2025-05-01)

Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel
by: Hakan Taban, et al.
Published: (2025-06-01)

MAIN MOLECULAR TARGETS FOR PROSTATE CANCER THERAPY
by: G. S. Krasnov, et al.
Published: (2016-02-01)

The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate
by: Caio Vinícius Suartz, et al.
Published: (2024-08-01)

Oral mucositis with abiraterone acetate: A therapeutic dilemma
by: Shaunak Valame, et al.
Published: (2020-01-01)

A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer
by: Xiaolin Lu, et al.
Published: (2025-05-01)

Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients
by: Yong Ma, et al.
Published: (2025-03-01)

Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer
by: Zhiyu Zhang, et al.
Published: (2025-08-01)

Prognostic factors for patients treated with abiraterone
by: Cecília M Alvim, et al.
Published: (2020-02-01)

Targeting the cancer cells and cancer‐associated fibroblasts with next‐generation FGFR inhibitors in prostate cancer co‐culture models
by: Syeda Afshan, et al.
Published: (2024-09-01)

ECM-mimicking hydrogel models of human adipose tissue identify deregulated lipid metabolism in the prostate cancer-adipocyte crosstalk under antiandrogen therapy
by: Agathe Bessot, et al.
Published: (2025-02-01)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01)

Two restraining devices in connection to surgical castration with or without local anesthesia: effects on piglet stress
by: Ann-Helena Hokkanen, et al.
Published: (2025-04-01)

The Use of Lidocaine-Infused Castration Bands to Castrate Beef–Dairy Calves and Its Effect on Animal Welfare and Performance
by: Madeline R. Mancke, et al.
Published: (2025-02-01)

THERMAL CASTRATION AS A METHOD OF GAMETOPHYTIC SELECTION TO INCREASE ADAPTABILITY
by: A. N. Borovik, et al.
Published: (2018-05-01)

Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer
by: Kaichen Zhou, et al.
Published: (2025-04-01)

Prognostic value of prostate-specific antigen in advanced prostate cancer treated with androgen deprivation therapy and abiraterone
by: L. Lou, et al.
Published: (2024-11-01)

A Case Report of Self-Inflicted Surgical Castration
by: Koo Han Yoo, et al.
Published: (2023-12-01)

Physician and Patient Preferences for the Treatment of Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer: A Best-Worst Scaling Study in Japan
by: Takahiro Kimura, et al.
Published: (2025-02-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)

Impact of Burdizzo and Surgical Castration on Immune and Oxidative Stress Markers in Cattle
by: Thanyakorn Chalalai, et al.
Published: (2025-06-01)

Amphibian newts as experimental models for studying weight gain after castration
by: Mai Takehara, et al.
Published: (2024-02-01)

Role of exosomes in castration-resistant prostate cancer
by: Yuan Cao, et al.
Published: (2025-05-01)

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
by: Zhe Zhu, et al.
Published: (2024-11-01)

Philosophical Foundation of Chemical Castration for Offenders of Sexual Violence Against Children
by: Henny Yuningsih, et al.
Published: (2020-01-01)

A novel lncRNA FLJ promotes castration resistance in prostate cancer through AR mediated autophagy
by: Yingying Wu, et al.
Published: (2025-03-01)

Screening and validation of key genes involved in castration-resistant prostate cancer based on transcriptomics sequencing
by: Guangquan Tong, et al.
Published: (2025-07-01)

The Activation of PI3K/AKT/mTOR Signaling Pathway in Response to Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer Cells
by: Işıl Ezgi Eryılmaz, et al.
Published: (2021-12-01)

Synergistic anticancer effect of CDRI-08 and Abiraterone acetate against castration resistant prostate cancer targeting PI3K/Akt pathway
by: Bhavana Jonnalagadda, et al.
Published: (2025-09-01)

FATTY ACID COMPOSITION OF LONGISSIMUS DORSI MUSCLE OF BLACK GOATS AND MERIZ KIDS AS INFLUENCED BY CASTRATION AND SLAUGHTER WEIGHT
by: Chinar Hassan, et al.
Published: (2023-03-01)

Ratio Legis of Chemical Castration to the Perpetrators of Sexual Violence against Children
by: Henny Yuningsih
Published: (2020-07-01)

Long-term ultrasonographic changes of the canine prostate gland after castration
by: Stefano Spada, et al.
Published: (2025-01-01)

Effect of castration and days on feed on body composition, glucose tolerance, and muscle gene expression in Nellore cattle
by: Luiz Henrique Pereira Silva, et al.
Published: (2025-08-01)

Treatment decision-making and treatment experiences in men with metastatic castration-resistant prostate cancer
by: Sandra Doveson, et al.
Published: (2025-03-01)

The Prognostic and Predictive Roles of Ataxia–Telangiectasia Mutated (ATM) Expression in Patients with Metastatic Non-Small-Cell Lung Cancer Receiving Pembrolizumab Monotherapy Alone or in Combination with Chemotherapy
by: Jamshid Hamdard, et al.
Published: (2025-04-01)